or Try an Advanced Search...

    Technical Analysis for GERN - Geron Corporation

    Grade Last Price % Change Price Change
    B 4.34 2.36% 0.10
    GERN closed up 2.36 percent on Monday, July 1, 2024, on 65 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical GERN trend table...
    Date Alert Name Type % Chg
    Stochastic Reached Oversold Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Fell Below 20 DMA Bearish 2.36%
    Wide Bands Range Expansion 2.36%
    Down 3 Days in a Row Weakness 2.36%
    Down 4 Days in a Row Weakness 2.36%
    Down 5 Days in a Row Weakness 2.36%
    20 DMA Support Bullish -2.25%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.25%
    Older End-of-Day Signals for GERN ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Resistance about 8 hours ago
    Rose Above Previous Day's High about 9 hours ago
    Up 5% about 9 hours ago
    Up 3% about 10 hours ago
    Up 2% about 10 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    GERN Chart by TradingView
    Basic chart:

    Profile

    Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Life Sciences Biology Stem Cell Senescence Geron Corporation Haematopoiesis

    Is GERN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 5 bullish, 0 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 13 Geron Corporation's (NASDAQ:GERN) large institutional owners must be happy as stock continues to impress, up 27% over the past week
    Jun 11 3 Penny Stocks to Buy if You Want to Spend Less and Earn More
    Jun 10 Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
    Jun 10 ICC Holdings, Diamond Offshore Drilling, CrowdStrike And Other Big Stocks Moving Higher On Monday
    Jun 10 Geron started at overweight at Barclays following imetelstat approval
    Jun 8 Geron: Innovative Rytelo Enters A Challenging MDS Market
    Jun 8 Is Geron Stock a Buy Following Its First New Drug Approval?
    Jun 7 Geron stock pops on FDA approval for blood cancer drug
    Jun 7 Gold Falls Sharply; Geron Shares Spike Higher
    Jun 7 Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?
    See more GERN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.34
    52 Week Low 1.64
    Average Volume 12,290,855
    200-Day Moving Average 2.67
    50-Day Moving Average 4.04
    20-Day Moving Average 4.51
    10-Day Moving Average 4.49
    Average True Range 0.27
    RSI (14) 50.98
    ADX 25.97
    +DI 23.77
    -DI 23.02
    Chandelier Exit (Long, 3 ATRs) 4.54
    Chandelier Exit (Short, 3 ATRs) 4.03
    Upper Bollinger Bands 5.25
    Lower Bollinger Band 3.76
    Percent B (%b) 0.39
    BandWidth 33.03
    MACD Line 0.13
    MACD Signal Line 0.20
    MACD Histogram -0.0701
    Fundamentals Value
    Market Cap 2.36 Billion
    Num Shares 543 Million
    EPS -0.34
    Price-to-Earnings (P/E) Ratio -12.76
    Price-to-Sales 3614.72
    Price-to-Book 3.94
    PEG Ratio -2.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.71
    Resistance 3 (R3) 4.72 4.60 4.65
    Resistance 2 (R2) 4.60 4.51 4.60 4.63
    Resistance 1 (R1) 4.47 4.45 4.54 4.46 4.61
    Pivot Point 4.36 4.36 4.39 4.35 4.36
    Support 1 (S1) 4.23 4.26 4.29 4.22 4.07
    Support 2 (S2) 4.11 4.20 4.11 4.05
    Support 3 (S3) 3.98 4.11 4.03
    Support 4 (S4) 3.97